ReviewMolecular diversity2026
Porphyrin/metalloporphyrin and their conjugates: a promising platform for drug delivery.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MOF-inspired porphyrinic single sites as promising platforms for stable immobilization of 2-thiouracil: a DFT study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Porphyrins and metalloporphyrins are emerging as versatile platforms for advanced drug delivery due to their unique structural, photophysical, and coordination properties. These macrocyclic compounds, known for their chemical stability and capacity to chelate various metal ions, address critical challenges in drug delivery, including poor solubility, non-specific toxicity, and limited control over drug release. This review explores synthetic strategies for porphyrins and their metal complexes, including classical and green methods, and highlights their therapeutic applications through diverse nanocarrier systems, such as gold nanoparticles, cyclodextrin conjugates, mesoporous silica, liposomes, and metal-organic frameworks. These systems offer stimuli-responsive, targeted, and synergistic therapeutic functionalities-especially in cancer therapy-by combining chemotherapy with photodynamic or sonodynamic modalities. Despite their promise, limitations persist, including scalability issues, potential metal toxicity, and insufficient long-term biocompatibility data. The review outlines future directions, advocating for AI-driven design, sustainable synthesis, and expanded applications beyond oncology, emphasizing the need for systematic comparative studies and clinical translation efforts.
Indexed as
Identifiers
40663246What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.